Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

John R Corboy

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-NEUR General Operations
Phone303/724-2196

    Collapse Research 
    Collapse research activities and funding
    R03MH056832     (CORBOY, JOHN R)Jul 1, 1997 - Jun 30, 2000
    NIH
    GENE EXPRESSION STUDIES USING BRAIN DERIVED HIV1 LTRS
    Role: Principal Investigator
    K08NS001673     (CORBOY, JOHN R)Jul 1, 1993 - Jun 30, 1998
    NIH
    MODELS OF AIDS DEMENTIA COMPLEX
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069359. PMID: 35024160.
      View in: PubMed
    2. Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 07 01; 78(7):787-788. PMID: 33871561.
      View in: PubMed
    3. Piquet AL, Corboy JR, Vollmer TL. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211019567. PMID: 34104219.
      View in: PubMed
    4. Corboy JR, Jones EC, Barbano RL, Anderson DC. 2019-2020: A Message From the Editors to Our Reviewers. Neurol Clin Pract. 2021 Feb; 11(1):e1-e5. PMID: 33968478.
      View in: PubMed
    5. Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020; 11:1045. PMID: 33071934.
      View in: PubMed
    6. Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2020 Aug 24. PMID: 32852530.
      View in: PubMed
    7. Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476. PMID: 32767538.
      View in: PubMed
    8. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 09; 7(9):1477-1487. PMID: 32767531.
      View in: PubMed
    9. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov; 36:101402. PMID: 31542710.
      View in: PubMed
    10. Mowry EM, Corboy JR. Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. Lancet Neurol. 2019 11; 18(11):983-985. PMID: 31492653.
      View in: PubMed
    11. Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun; 25(3):715-735. PMID: 31162313.
      View in: PubMed
    12. Corboy JR, Powers LB, Anderson DC, Barbano RL. Message from the Editors to our Reviewers. Neurol Clin Pract. 2019 Apr; 9(2):90-92. PMID: 31041121.
      View in: PubMed
    13. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):845-854. PMID: 30794930.
      View in: PubMed
    14. Corboy JR. Giving voice to patients. Neurol Clin Pract. 2019 Feb; 9(1):1. PMID: 30858995.
      View in: PubMed
    15. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732. PMID: 30635477.
      View in: PubMed
    16. Corboy JR. Strength in numbers. Neurol Clin Pract. 2018 Oct; 8(5):363. PMID: 30564476.
      View in: PubMed
    17. Corboy JR. Real-world practice. Neurol Clin Pract. 2018 Aug; 8(4):275. PMID: 30140570.
      View in: PubMed
    18. Corboy JR. Partners in enhancing functional ability and well-being. Neurol Clin Pract. 2018 Apr; 8(2):83. PMID: 29708226.
      View in: PubMed
    19. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29801915.
      View in: PubMed
    20. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30105154.
      View in: PubMed
    21. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30107012.
      View in: PubMed
    22. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30105147.
      View in: PubMed
    23. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29443296.
      View in: PubMed
    24. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30140580.
      View in: PubMed
    25. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 1465618.
      View in: PubMed
    26. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29473609.
      View in: PubMed
    27. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30588371.
      View in: PubMed
    28. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29685920.
      View in: PubMed
    29. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30847358.
      View in: PubMed
    30. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 31644992.
      View in: PubMed
    31. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34364034.
      View in: PubMed
    32. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35145470.
      View in: PubMed
    33. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30386250.
      View in: PubMed
    34. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19444532.
      View in: PubMed
    35. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16157741.
      View in: PubMed
    36. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17000957.
      View in: PubMed
    37. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16216934.
      View in: PubMed
    38. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17365249.
      View in: PubMed
    39. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19171823.
      View in: PubMed
    40. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12928426.
      View in: PubMed
    41. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23725360.
      View in: PubMed
    42. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17024655.
      View in: PubMed
    43. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17947712.
      View in: PubMed
    44. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25878010.
      View in: PubMed
    45. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9484350.
      View in: PubMed
    46. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26621682.
      View in: PubMed
    47. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15327035.
      View in: PubMed
    48. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24790801.
      View in: PubMed
    49. Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018; 13(2):e0192109. PMID: 29394264.
      View in: PubMed
    50. Corboy JR, Powers LB, Anderson DC, Barbano RL. Message from the Editors to our Reviewers. Neurol Clin Pract. 2018 Feb; 8(1):2-3. PMID: 29517054.
      View in: PubMed
    51. Corboy JR. The physician as captain of the patient-centered ship. Neurol Clin Pract. 2018 Feb; 8(1):1. PMID: 29517064.
      View in: PubMed
    52. Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). Neurology. 2018 02 27; 90(9):e797-e807. PMID: 29386274.
      View in: PubMed
    53. Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep; 3(3):2055217317725102. PMID: 28839949.
      View in: PubMed
    54. Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017 Sep; 13(9):567-572. PMID: 28799551.
      View in: PubMed
    55. Corboy JR. Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary. Mult Scler. 2017 08; 23(9):1192-1193. PMID: 28673113.
      View in: PubMed
    56. Hardy TA, Corboy JR, Weinshenker BG. Baló concentric sclerosis evolving from apparent tumefactive demyelination. Neurology. 2017 05 30; 88(22):2150-2152. PMID: 28468846.
      View in: PubMed
    57. Kister I, Corboy J. Author response: Reducing costs while enhancing quality of care in MS. Neurology. 2017 03 21; 88(12):1212. PMID: 28320926.
      View in: PubMed
    58. Kister I, Corboy JR. Reducing costs while enhancing quality of care in MS. Neurology. 2016 Oct 11; 87(15):1617-1622. PMID: 27590294.
      View in: PubMed
    59. Klein E, Solomon AJ, Corboy J, Bernat J. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. Mult Scler Relat Disord. 2016 Jul; 8:4-8. PMID: 27456867.
      View in: PubMed
    60. Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro Oncol. 2016 Mar; 18 Suppl 2:ii13-ii20. PMID: 26989128.
      View in: PubMed
    61. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016 Mar 15; 86(11):1014-21. PMID: 26888980.
      View in: PubMed
    62. McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. J Manag Care Spec Pharm. 2015 Mar; 21(3):210-8b. PMID: 25726030.
      View in: PubMed
    63. Solomon AJ, Klein EP, Corboy JR, Bernat JL. Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. Mult Scler. 2015 Oct; 21(12):1593-9. PMID: 25716879.
      View in: PubMed
    64. Larsen DP, Butler AC, Aung WY, Corboy JR, Friedman DI, Sperling MR. The effects of test-enhanced learning on long-term retention in AAN annual meeting courses. Neurology. 2015 Feb 17; 84(7):748-54. PMID: 25609761.
      View in: PubMed
    65. Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014 Nov; 3(6):696-704. PMID: 25891548.
      View in: PubMed
    66. Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 May 15; 270(1-2):75-85. PMID: 24690203.
      View in: PubMed
    67. Lafosse JM, Mitchell SM, Corboy JR, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc. 2013 Oct; 19(9):995-1008. PMID: 24059259.
      View in: PubMed
    68. Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS. The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10; 81(11):1022-3. PMID: 24019388.
      View in: PubMed
    69. Corboy JR. Annual checkup. Neurol Clin Pract. 2012 Dec; 2(4):263-264. PMID: 30123676.
      View in: PubMed
    70. Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May; 38(1):37-42. PMID: 23200463.
      View in: PubMed
    71. Corboy JR. Practice across borders. Neurol Clin Pract. 2012 Sep; 2(3):169-170. PMID: 29443291.
      View in: PubMed
    72. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 Jul; 71(7):604-17. PMID: 22710964.
      View in: PubMed
    73. Schowinsky J, Corboy J, Vollmer T, Kleinschmidt-DeMasters BK. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012 May; 123(5):751-2. PMID: 22407011.
      View in: PubMed
    74. Corboy JR. Call for submissions! Neurol Clin Pract. 2012 Mar; 2(1):1-2. PMID: 29443282.
      View in: PubMed
    75. Corboy JR. Breaking clinical ground. Neurol Clin Pract. 2011 Dec; 1(1):1. PMID: 29443314.
      View in: PubMed
    76. Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Phys Ther. 2011 Aug; 91(8):1166-83. PMID: 21680771.
      View in: PubMed
    77. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98. PMID: 21651327.
      View in: PubMed
    78. Freeman WD, Nolte CM, Matthews BR, Coleman M, Corboy JR. Results of the American Academy of Neurology resident survey. Neurology. 2011 Mar 29; 76(13):e61-7. PMID: 21444895.
      View in: PubMed
    79. Miravalle A, Corboy JR. Therapeutic options in multiple sclerosis: five new things. Neurology. 2010 Nov 02; 75(18 Suppl 1):S22-7. PMID: 21041767.
      View in: PubMed
    80. Corboy JR, Miravalle AA. Emerging therapies for treatment of multiple sclerosis. J Inflamm Res. 2010; 3:53-9. PMID: 22096357.
      View in: PubMed
    81. Haug A, Mahalingam R, Cohrs RJ, Schmid DS, Corboy JR, Gilden D. Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system: Case report and review of the literature. J Neurol Sci. 2010 May 15; 292(1-2):85-8. PMID: 20170926.
      View in: PubMed
    82. Butler MA, Corboy JR, Filley CM. How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis. Neuropsychol Rev. 2009 Sep; 19(3):399-410. PMID: 19373561.
      View in: PubMed
    83. Kleinschmidt-Demasters BK, Cummings TJ, Hulette CM, Morgenlander JC, Corboy JR. Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder. J Neuropathol Exp Neurol. 2009 Apr; 68(4):432-9. PMID: 19287308.
      View in: PubMed
    84. Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VF. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer. 2008 Oct; 8(5):449-52. PMID: 18952560.
      View in: PubMed
    85. Corboy JR, Elkind MS. Maintenance of certification: ready or not, here it comes. Neurology. 2008 Aug 19; 71(8):544-5. PMID: 18711107.
      View in: PubMed
    86. Gill DJ, Freeman WD, Thoresen P, Corboy JR. Residency training the neurology resident case log: a national survey of neurology residents. Neurology. 2007 May 22; 68(21):E32-3. PMID: 17515532.
      View in: PubMed
    87. Brousseau KM, Arciniegas DB, Carmosino MJ, Corboy JR. The differential diagnosis of Axis I psychopathology presenting to a university-based multiple sclerosis clinic. Mult Scler. 2007 Jul; 13(6):749-53. PMID: 17613603.
      View in: PubMed
    88. Corboy JR, Gault J, Kleinschmidt-DeMasters BK. An adult case of leukoencephalopathy with intracranial calcifications and cysts. Neurology. 2006 Nov 28; 67(10):1890-2. PMID: 17130435.
      View in: PubMed
    89. Hudson LA, Bernard TJ, Tseng BS, Miller BR, Corboy JR. Neuromyelitis optica immunoglobulin G in a child. Pediatr Neurol. 2006 Nov; 35(5):370-2. PMID: 17074612.
      View in: PubMed
    90. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 Jul; 63(7):964-8. PMID: 16831965.
      View in: PubMed
    91. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr; 63(4):614-9. PMID: 16606781.
      View in: PubMed
    92. Carmosino MJ, Brousseau KM, Arciniegas DB, Corboy JR. Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol. 2005 Apr; 62(4):585-90. PMID: 15824257.
      View in: PubMed
    93. Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, Filley CM. Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol. 2005 Mar; 36(3):282-90. PMID: 15791573.
      View in: PubMed
    94. Ritchie AM, Gilden DH, Williamson RA, Burgoon MP, Yu X, Helm K, Corboy JR, Owens GP. Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol. 2004 Jul 01; 173(1):649-56. PMID: 15210828.
      View in: PubMed
    95. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 May 15; 363(9421):1607-8. PMID: 15145635.
      View in: PubMed
    96. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, Kramer PD. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003 Sep 23; 61(6):848-50. PMID: 14504338.
      View in: PubMed
    97. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 09; 61(5):602-11. PMID: 12963748.
      View in: PubMed
    98. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003 Oct 01; 102(7):2364-72. PMID: 12763935.
      View in: PubMed
    99. Corboy JR, Goodin DS, Frohman EM. Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol. 2003 Jan; 5(1):35-54. PMID: 12521562.
      View in: PubMed
    100. Corboy JR, Boudreau E, Morgenlander JC, Rudnicki S, Coyle PK. Neurology residency training at the millennium. Neurology. 2002 May 28; 58(10):1454-60. PMID: 12034779.
      View in: PubMed
    101. Corboy JR. Patent foramen ovale, atrial septal aneurysm, and recurrent stroke. N Engl J Med. 2002 Apr 25; 346(17):1331-2; author reply 1331-2. PMID: 11973372.
      View in: PubMed
    102. Ross HL, Gartner S, McArthur JC, Corboy JR, McAllister JJ, Millhouse S, Wigdahl B. HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity. J Neurovirol. 2001 Jun; 7(3):235-49. PMID: 11517398.
      View in: PubMed
    103. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L, Carlson S, Corboy J, Parren PW, Sanna PP, Gilden DH, Burton DR. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1793-8. PMID: 11172030.
      View in: PubMed
    104. Singh M, Corboy JR, Stears JC, Kleinschmidt-DeMasters BK. Diffuse leptomeningeal gliomatosis associated with multifocal CNS infarcts. Surg Neurol. 1998 Oct; 50(4):356-62; discussion 362. PMID: 9817460.
      View in: PubMed
    105. Corboy JR, Garl PJ. HIV-1 LTR DNA sequence variation in brain-derived isolates. J Neurovirol. 1997 Oct; 3(5):331-41. PMID: 9372454.
      View in: PubMed
    106. Corboy JR. Physician-assisted suicide. N Engl J Med. 1997 Feb 06; 336(6):439; author reply 440-1. PMID: 9011809.
      View in: PubMed
    107. Corboy J, Herbison P. Trainee interns: education and service roles. N Z Med J. 1993 Oct 13; 106(965):431-2. PMID: 8414282.
      View in: PubMed
    108. Corboy JR, Price RW. Myelitis and toxic, inflammatory, and infectious disorders. Curr Opin Neurol Neurosurg. 1993 Aug; 6(4):564-70. PMID: 8400470.
      View in: PubMed
    109. Corboy JR. CD4+ T-lymphocytopenia without HIV infection. N Engl J Med. 1993 Jun 24; 328(25):1849; author reply 1849-50. PMID: 8099200.
      View in: PubMed
    110. Corboy JR, Galetta SL. Familial cavernous angiomas manifesting with an acute chiasmal syndrome. Am J Ophthalmol. 1989 Sep 15; 108(3):245-50. PMID: 2774032.
      View in: PubMed
    111. Corboy JR, Fink L, Miller WT. Congestive cardiomyopathy in association with AIDS. Radiology. 1987 Oct; 165(1):139-41. PMID: 3498183.
      View in: PubMed
    Corboy's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (329) concept(s)
    _
    Co-Authors Expand Description
    See all (27) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)